The pharmaceuticals manufacturing industry in India is expected to be worth $41.92 billion by 2020, expanding at a compound annual growth rate (CAGR) of 19.76% from 2015 to 2020.
This is despite slowing growth in developed markets; players in generics are expected to perform reasonably well due to significant numbers of exclusivity losses and patent expirations on leading drugs in the upcoming years, according to a new report from researchandmarkets, titled “Pharmaceuticals Manufacturing Industry in India 2015-2020.”
In the throes of big changes
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze